MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma

Summary

This phase I trial studies best dose and side effects of oncolytic adenovirus DNX-2401 in treating patients with high-grade glioma that has come back (recurrent). Oncolytic adenovirus DNX-2401 is made from the common cold virus that has been changed in the laboratory to make it less likely to cause an infection (such as a cold). The virus is also changed to target brain cancer cells and attack them.

Timeline

Start

2019-02-12

Primary completion

2027-09-30

Completion

2027-09-30

Publications

• Chen SR, Chen MM, Ene C, Lang FF, Kan P. Perfusion-guided endovascular super-selective intra-arterial infusion for treatment of malignant brain tumors. J Neurointerv Surg. 2022 Jun;14(6):533-538. doi: 10.1136/neurintsurg-2021-018190. Epub 2021 Nov 25.

Drugs

Indications